Blood cancer type
acute myeloid leukemia (AML)
Defining targets of MDS to AML progression
Leukemia impacts thousands of Canadians. Developing effective treatments is limited by incomplete understanding of how normal blood cells become leukemic in the first place. Using our recently created model system where normal blood cells can be progressively turned into leukemia, we aim to define the genes that are activated and inactivated when healthy cells turn leukemic, and use new drugs to inhibit these changes to prevent leukemia from starting.